

Dr Martin Landray is a Reader in Epidemiology and Honorary Consultant Physician at Oxford University. He has substantial experience of conducting large-scale, international clinical trials in cardiovascular and renal disease (including the SHARP, THRIVE and REVEAL trials). He continues to develop and promote methods to facilitate the conduct of large-scale trials to generate reliable results that will improve healthcare. He was one of three team leaders on the FDA Clinical Trial Transformation Initiative (CTTI) Monitoring Project which published its recommendations in 2011 and influenced regulatory guidance on the role of monitoring in both the USA and Europe. He is now playing a similar role in CTTI's on-going Quality by Design project.